Loading…
for educational and safety purposes
Aniracetam and Oxiracetam both come up in the same conversations; they overlap on Glutamate and Acetylcholine. Aniracetam: Aniracetam is a fat-soluble member of the racetam family and one of the original ampakines, a positive allosteric modulator of AMPA-type glutamate receptors used as a cognition enhancer. Oxiracetam: Oxiracetam is a synthetic compound from the racetam family and a close chemical relative of piracetam; it was developed in Italy in the 1980s as a prescription drug for memory and attention problems in dementia.
Aniracetam is a fat-soluble member of the racetam family and one of the original ampakines, a positive allosteric modulator of AMPA-type glutamate receptors used as a cognition enhancer. By slowing the desensitization of these excitatory receptors it strengthens the synaptic transmission tied to learning and memory, and it has been used clinically abroad for cognitive symptoms after stroke and in dementia. Its principal metabolite, 2-pyrrolidinone, has been reported to produce a longer-lasting enhancement of AMPA-receptor function through a CaMKII-dependent pathway. It is also noted for anxiolytic and mood effects in animal models.
Oxiracetam is a synthetic compound from the racetam family and a close chemical relative of piracetam; it was developed in Italy in the 1980s as a prescription drug for memory and attention problems in dementia. Older European trials in dementia patients generally reported small improvements on cognitive test scores, but the modern evidence is split: a 590-patient Chinese trial in traumatic brain injury found a real benefit, while a 500-patient Korean trial found none for preventing cognitive decline after stroke, and South Korea then withdrew the drug. Nobody has established how it works; a standard 19-target receptor screen found no measurable binding at concentrations up to 30 micromolar, and no binding constant for oxiracetam at any brain receptor exists in the published literature. It remains in clinical use in China and is sold elsewhere as an unapproved powder, with a mild side-effect record but no trial evidence at all that it improves cognition in healthy people.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
positive modulator
positive modulator
increases
increases
mild agonist
modulates
Upregulation (enantiomer-specific, indirect, protein-expression level)
Positive modulation (functional; increases agonist efficacy, not potency)
No measurable activity; this is a negative result and the best-supported target fact about the compound
Indirect presynaptic enhancement
Biphasic enhancement, with an inverted-U concentration response
Reversal of kynurenic acid antagonism
boosts
Transient activator followed by down-regulation
facilitates
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Oxiracetam is currently listed by more trusted vendors (3), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.